Robert Rubenstein, MD
Neurology · Silverdale, WANPI 1437185279
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,723 of the $98,589 with a category attached, or 78.8%. AbbVie accounts for 83.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $29,237 and has fallen 88.8% since, to $3,276 in 2025. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 921 payments — averaging $107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Sanofi$1K
- Novartis$1K
- Teva Pharmaceuticals USA, Inc.$999
- AstraZeneca$856
- EMD Serono, Inc.$789
- plus $11K from 54 others
What the payments were for
- Consulting fees$4270%
- Speaking & faculty fees$77,72379%
- Travel & lodging$3,0683%
- Food & beverage$16,78417%
- Education$5871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,589 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 24 | $616,237 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 41 | $574,478 |
| IngrezzaValbenazine Tosylate | 31 | $250,810 |
| NuplazidPimavanserin Tartrate | 45 | $214,448 |
| TysabriNatalizumab | 12 | $99,497 |
| AustedoDeutetrabenazine | 11 | $71,075 |
| AmpyraDalfampridine | 12 | $50,061 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $28,947 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $24,161 |
| XcopriCenobamate | 17 | $21,546 |
| UbrelvyUbrogepant | 12 | $16,904 |
| QuliptaAtogepant | 12 | $12,333 |
| Lamotrigine ErLamotrigine | 16 | $10,572 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 446 | $10,465 |
| Memantine Hcl | 377 | $9,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $856 | $616,23724 claims |
| Grifols USA, LLCGamunex-C | $60 | $574,47841 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $309 | $250,81031 claims |
| Acadia Pharmaceuticals IncNuplazid | $637 | $214,44845 claims |
| BiogenTysabri | $699 | $99,49712 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $999 | $71,07511 claims |
| Acorda Therapeutics, IncAmpyra | $353 | $50,06112 claims |
| AbbVieUbrelvy, Qulipta | $82,614 | $29,23824 claims |
| SK Life Science, Inc.Xcopri | $319 | $21,54617 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $341 | $3,04159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Silverdale
- Eric LeeSilverdale$14K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
- Pravin KhemaniSeattle$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.